myeloablation

myeloablation

 [mi″ĕ-lo-ab-la´shun]
severe myelosuppression. adj., adj myeloab´lative.

myeloablation

(mī″ĕ-lō-a-blā′shŏn) [ myelo- + ablation]
Suppression of the ability of bone marrow to produce blood cells, e.g., by chemotherapy or radiation therapy.
References in periodicals archive ?
It is common (40-100% incidence) in patients undergoing high dose chemotherapy and hematopoietic cell transplantation, where the incidence and severity of oral mucositis depends greatly on the nature of the conditioning regimen used for myeloablation.
Patients will undergo a conditioning regimen administration with busulfan intravenously for four days to achieve myeloablation prior to the transplant.
Follow-up showed that, among the patients who underwent myeloablation and autologous transplant with hematopoietic stem cells, there were no long-term deaths or cancers, there was an 88% survival rate, and 92% remained off disease-modifying treatment, Keith M.
Iomab-B is intended to provide safer myeloablation of the bone marrow prior to a bone marrow transplant, thus providing a potentially curative treatment option for this patient population and for patients with other leukemias, lymphomas, myelomas and other blood disorders.
Saxena et al., "Derivation of hepatocytes from bone marrow cells in mice after radiation-induced myeloablation," Hepatology, vol.
The options of (A) conditioning with alemtuzumab, treosulfan, fludarabine, and thiotepa using a TCR-alpha and -beta depleted graft versus (B) using a T-cell replete marrow graft after cyclophosphamide 14, 5 mg/kg days -6 and -5, flu 30 mg/[m.sup.2] days -6 to -2 (5 days), and 200 cGy TBI day -1 [15] with the addition of busulfan 3.2 mg/kg/day, days -4 and -3 to achieve myeloablation [16] as conditioning and posttransplant cyclophosphamide 50 mg/kg days +3 and +4 and tacrolimus and mycophenolate mofetil as graft-versus-host-disease (GVHD) prophylaxis [15] were discussed.
Most (16) had high-intensity myeloablation; the remainder had reduced-intensity conditioning.
Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells.
This finding along with the STAT4 genomic signature of CD11b+ cells isolated from adipose tissue of the two chimeric groups also suggests that myeloablation does not completely remove the adipose tissue resident myeloid population (Figure 3(e)).
Transplant modalities included combinations of matched/mismatched and related/unrelated donors from umbilical cord blood, peripheral blood, and bone marrow, with or without myeloablation. Therapies for GVHD included steroids, mycophenolate mofetil, tacrolimus, sirolimus, denileukin diftitox, and infliximab.
Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis.